Zydus Cadila has received the final approval from the USFDA to market Allopurinol Tablets USP, 100 mg and 300 mg. The drug is indicated in the management of patients with gout and patients with cancer who are receiving therapy that causes elevations of serum and urinary uric acid levels. It will be manufactured at the group's formulations manufacturing facility at Baddi.
The sales of Allopurinol Tablets USP are estimated at $141.2 million. Source: IMS Health, IMS National Sales Perspective Audit, MAT August 2017, extracted October 2017
The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.492 as compared to the previous close of Rs. 492.15. The total number of shares traded during the day was 13321 in over 309 trades.
The stock hit an intraday high of Rs. 495.5 and intraday low of 487. The net turnover during the day was Rs. 6544687.